Beschrijving
BPC-157, TB-500, CJC-1295, and other peptides are being promoted for faster recovery, tissue repair, muscle growth, and longevity, often with confident claims that run far ahead of the human evidence. Some have intriguing animal data or histories in pharmaceutical development. But many of the compounds people are actually buying today are unapproved, poorly studied in humans, and sold through a gray market where purity, dosing, and even what’s in the vial can be uncertain.
Mike Haney talks with Johns Hopkins physician-scientist Dr. Christopher Robinson about how this market got so far ahead of the science, whether any of these compounds may ultimately prove useful, and what evidence would be required to find out. Robinson is interested enough in their potential to try to study them rigorously, but says the current evidence is not enough for him to recommend that people use them.
Free course: Improve your metabolic health
Get our free email course on how glucose, nutrition, exercise, sleep, and measurement can help you build habits that support better energy and long-term health: https://levels.link/wnl
What We Cover:
• What BPC-157, TB-500, CJC-1295 and other popular peptides are supposed to do
• Why Robinson would tell a friend to hold off on BPC-157 today
• The safety and regulatory problems created by the current gray market
• Why money, patentability, and academic stigma have slowed human trials
• How Robinson would design a placebo-controlled BPC-157 trial using wearables, imaging, and longer-term follow-up
🎙️ About the Guest:
Dr. Christopher Robinson is a physician-scientist and Assistant Professor of Anesthesiology and Critical Care Medicine at Johns Hopkins, specializing in pain and regenerative medicine. He is pursuing an ARPA-H-funded study of BPC-157 that would test its safety and efficacy in a rigorous placebo-controlled human trial.
📍What Dr. Christopher Robinson & Mike Haney discussed:
• 00:04 - Prove it against placebo, then show the change in steps and on an MRI
• 04:14 - He was using peptides to steer stem cells 20 years before the craze
• 05:39 - A peptide is a short amino-acid chain. Insulin and GLP-1s already count
• 08:23 - Few new pain drugs, then RFK on Rogan, and the craze took off
• 10:45 - BPC-157 came from one Croatian lab. No human gene, no known receptor
• 15:01 - Thirty years on, the human evidence is still about 14 people
• 18:19 - Growth-hormone peptides can enlarge the tissue you do not want
• 23:00 - Off-label, compounded, and research-only are three different things
• 27:58 - Off the compounding list, into a gray market. Compounding is still not FDA approval
• 32:06 - Millions are already injecting them. He wants the supply regulated
• 36:52 - He would tell a friend with a bad shoulder to wait
• 38:37 - Knee osteoarthritis, double-blind, then a crossover
• 44:33 - Academics called it fringe, and no one can patent the molecule
• 48:41 - The future he wants is a peptide picked from your data…
Website: podcasters.spotify.com

